Intercell has reported that interim data from a phase II clinical trial investigating the vaccine candidate for the prevention of infections with the bacterium pseudomonas aeruginosa are available.
Hospira and Orchid Chemicals & Pharmaceuticals have announced an agreement for Hospira to acquire Orchid’s generic injectable finished-dosage form pharmaceuticals business for approximately $400m. The acquisition includes Orchid’s
Auxilium has reported top-line efficacy and safety results for the phase IIb clinical trial for Xiaflex (collagenase clostridium histolyticum) in the treatment of peyronie’s disease. The phase IIb
Naurex has initiated a Phase I clinical trial of its GLYX-13 and has successfully dosed the first subjects in the study. GLYX-13, a glycine site functional partial agonist
Makefield Therapeutics has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield’s biodegradable Hybrid Nanoparticles, a new drug delivery
Neptune Technologies & Bioressources (Neptune) announces additional preclinical research results on its Acasti Pharma (Acasti) drug development program. Acasti announces the results of additional preclinical research designed to
EuroPharma has signed an exclusive multi-year contract with DolCas Biotech (DolCas) for the use of absorbency BCM-95 curcumin and specialised BosPure boswellia in multiple EuroPharma formulations. Reportedly, the
GlaxoSmithKline (GSK) and NanoBio has entered into an exclusive licensing agreement in the US and Canada for the over-the-counter (OTC) use of NB-001, a patented compound representing the
Merck KGaA (Merck) has inaugurated the expansion of its Advanced Technologies Centre at Chilworth near Southampton, the UK. For around ten years, the Chilworth site has served as
WaferGen is going to launch the human MicroRNA panel for its service for gene-expression profiling using its SmartChip real-time PCR system. The human MicroRNA panel provides a comprehensive
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.